Should I buy or sell Replimune Group stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REPL shares. View REPL analyst ratings or view top-rated stocks .

What is Replimune Group's stock price target for 2024?

6 brokerages have issued 1-year target prices for Replimune Group's shares. Their REPL share price targets range from $34.00 to $70.00. On average, they expect the company's share price to reach $51.33 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View analysts price targets for REPL or view top-rated stocks among Wall Street analysts .

How have REPL shares performed in 2023?

Replimune Group's stock was trading at $27.20 at the start of the year. Since then, REPL stock has decreased by 54.7% and is now trading at $12.32. View the best growth stocks for 2023 here .

When is Replimune Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our REPL earnings forecast .

How were Replimune Group's earnings last quarter?

Replimune Group, Inc. (NASDAQ:REPL) posted its earnings results on Tuesday, November, 7th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by $0.10.

What ETFs hold Replimune Group's stock?

ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) , Horizon Kinetics Medical ETF (MEDX) , First Trust Innovation Leaders ETF (ILDR) . ALPS Medical Breakthroughs ETF (SBIO) ,

What other stocks do shareholders of Replimune Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU) , Myovant Sciences (MYOV) , Peabody Energy (BTUUQ) , AVEO Pharmaceuticals (AVEO) , Fate Therapeutics (FATE) , Immunomedics (IMMU) , Pfizer (PFE) , SCYNEXIS (SCYX) , Exelixis (EXEL) and Fulcrum Therapeutics (FULC) .

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (7.05%), Loomis Sayles & Co. L P (2.19%), FMR LLC (2.15%), Emerald Advisers LLC (1.78%), Emerald Mutual Fund Advisers Trust (1.48%) and Northern Trust Corp (0.77%). Insiders that own company stock include Colin Love , Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Konstantinos Xynos, Pamela Esposito , Philip Astley-Sparke, Robert Coffin , Sushil Patel and Tanya Lewis. View institutional ownership trends .

How do I buy shares of Replimune Group?

Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Replimune Group Stock Price, News & Analysis (NASDAQ:REPL)

$12.32

+0.61 (+5.21%)

(As of 12/4/2023 ET)

Compare

Today's Range: $11.35
▼
$12.38
50-Day Range: $10.18
▼
$17.11
52-Week Range: $9.79
▼
$29.52

Volume: 823,164 shs
Average Volume: 623,235 shs
Market Capitalization: $727.62 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $51.33

Replimune Group MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 316.7% Upside
$51.33 Price Target
Short Interest: Healthy
17.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.28
Upright™ Environmental Score
News Sentiment: 0.50
Based on 4 Articles This Week
Insider Trading: Selling Shares
$187,072 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.53) to ($3.93) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.47 out of 5 stars

Medical Sector

226th out of 952 stocks

Biological Products, Except Diagnostic Industry

27th out of 155 stocks

3.5

Analyst's Opinion

Consensus Rating
Replimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $51.33, Replimune Group has a forecasted upside of 316.7% from its current price of $12.32.
Amount of Analyst Coverage
Replimune Group has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
17.01% of the float of Replimune Group has been sold short.
Short Interest Ratio / Days to Cover
Replimune Group has a short interest ratio ("days to cover") of 9.7.
Change versus previous month
Short interest in Replimune Group has recently decreased by 15.48%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Replimune Group does not currently pay a dividend.
Dividend Growth
Replimune Group does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Replimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.
Environmental Sustainability
The Environmental Impact score for Replimune Group is -1.28.

2.5

News and Social Media Coverage

News Sentiment
Replimune Group has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Replimune Group this week, compared to 2 articles on an average week.
Search Interest
4 people have searched for REPL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $187,072.00 in company stock.
Percentage Held by Insiders
20.60% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Replimune Group are expected to decrease in the coming year, from ($3.53) to ($3.93) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Replimune Group is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Replimune Group is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Replimune Group has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Replimune Group Stock (NASDAQ:REPL)

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REPL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

REPL Stock News Headlines

December 3, 2023 | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Stock Price Down 3.4%

December 3, 2023 | americanbankingnews.com

Replimune Group, Inc. (NASDAQ:REPL) Given Average Recommendation of "Buy" by Brokerages

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

December 2, 2023 | americanbankingnews.com

Replimune Group Sees Unusually Large Options Volume (NASDAQ:REPL)

November 26, 2023 | benzinga.com

Replimune Group Stock (NASDAQ:REPL) Dividends: History, Yield and Dates

November 24, 2023 | benzinga.com

Replimune Group Stock (NASDAQ:REPL), Analyst Ratings, Price Targets, Predictions

November 8, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Scholar Rock Holding (SRRK), Replimune Group (REPL) and Precision BioSciences (DTIL)

November 8, 2023 | finance.yahoo.com

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

December 5, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 7, 2023 | msn.com

Replimune Group GAAP EPS of -$0.90 misses by $0.04

November 7, 2023 | finance.yahoo.com

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

November 5, 2023 | seekingalpha.com

Replimune: Skepticism Is Priced In Ahead Of Long-Awaited CERPASS Data (Rating Upgrade)

November 3, 2023 | finance.yahoo.com

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

November 2, 2023 | morningstar.com

Replimune Group Inc REPL

September 14, 2023 | finance.yahoo.com

Insider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group Inc

September 10, 2023 | fool.com

Replimune Group (NASDAQ: REPL)

August 14, 2023 | msn.com

Replimune: Q4 2023 Data Readouts Of RP1 Makes This A Must Watch

August 9, 2023 | msn.com

Unusual Put Option Trade in Replimune Group (REPL) Worth $810.00K

August 8, 2023 | markets.businessinsider.com

Arvinas Holding Company (ARVN) Receives a Buy from Barclays

August 3, 2023 | finance.yahoo.com

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

August 1, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Replimune Group

July 31, 2023 | finance.yahoo.com

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

July 20, 2023 | finance.yahoo.com

Replimune Announces Sander Slootweg will Depart from its Board of Directors

July 13, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Replimune Group (REPL)

July 9, 2023 | msn.com

Replimune: The Rise Of Oncolytic Virus Therapies In Cancer Treatment

June 28, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Aldeyra Therapeutics (ALDX), Replimune Group (REPL)

June 9, 2023 | msn.com

HC Wainwright & Co. Reiterates Replimune Group (REPL) Buy Recommendation

See More Headlines

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/05/2023
Next Earnings (Estimated): 2/08/2024
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:REPL
CUSIP: N/A
CIK: 1737953
Web: www.replimune.com
Phone: (781) 222-9600
Fax: N/A
Employees: 284
Year Founded: 2015

Price Target and Rating

Average Stock Price Target: $51.33
High Stock Price Target: $70.00
Low Stock Price Target: $34.00
Potential Upside/Downside: +316.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-174,280,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -37.28%
Return on Assets: -31.87%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 12.76
Quick Ratio: 12.76

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.80 per share
Price / Book: 1.26

Miscellaneous

Outstanding Shares: 59,060,000
Free Float: 46,893,000
Market Cap: $727.62 million
Optionable: Not Optionable
Beta: 1.45

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Philip Astley-Sparke F.S.A. (Age 52)
CEO & Director
Comp: $1.07M
Dr. Sushil Patel Ph.D. (Age 52)
Chief Strategy Officer
Comp: $665.05k
Dr. Robert Coffin Ph.D. (Age 58)
Founder, President, Chief Research & Development Officer and Director
Comp: $785.89k
Ms. Emily Luisa Hill (Age 43)
Chief Financial Officer
Dr. Colin A. Love Ph.D. (Age 65)
Chief Operating Officer
Comp: $419.37k
Mr. Andrew Schwendenman (Age 47)
Chief Accounting Officer & Treasurer
Dr. Pamela Esposito Ph.D. (Age 49)
Chief Business Officer
Comp: $464.63k
Ms. Tanya N. Lewis M.S. (Age 52)
Chief Development Operations Officer
Comp: $4.7k
Mr. Christopher Sarchi (Age 55)
Chief Commercial Officer
Dr. Konstantinos Xynos M.B.A. (Age 57)
M.D., Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

REPL Stock Analysis - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REPL shares.
View REPL analyst ratings or view top-rated stocks.
What is Replimune Group's stock price target for 2024?: 6 brokerages have issued 1-year target prices for Replimune Group's shares. Their REPL share price targets range from $34.00 to $70.00. On average, they expect the company's share price to reach $51.33 in the next year. This suggests a possible upside of 316.7% from the stock's current price.
View analysts price targets for REPL or view top-rated stocks among Wall Street analysts.
How have REPL shares performed in 2023?: Replimune Group's stock was trading at $27.20 at the start of the year. Since then, REPL stock has decreased by 54.7% and is now trading at $12.32.
View the best growth stocks for 2023 here.
When is Replimune Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our REPL earnings forecast.
How were Replimune Group's earnings last quarter?: Replimune Group, Inc. (NASDAQ:REPL) posted its earnings results on Tuesday, November, 7th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by $0.10.
What ETFs hold Replimune Group's stock?: ETFs with the largest weight of Replimune Group (NASDAQ:REPL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Horizon Kinetics Medical ETF (MEDX), First Trust Innovation Leaders ETF (ILDR).ALPS Medical Breakthroughs ETF (SBIO),

What other stocks do shareholders of Replimune Group own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).
When did Replimune Group IPO?: (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.
Who are Replimune Group's major shareholders?: Replimune Group's stock is owned by a number of institutional and retail investors. Top institutional investors include Redmile Group LLC (7.05%), Loomis Sayles & Co. L P (2.19%), FMR LLC (2.15%), Emerald Advisers LLC (1.78%), Emerald Mutual Fund Advisers Trust (1.48%) and Northern Trust Corp (0.77%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Konstantinos Xynos, Pamela Esposito, Philip Astley-Sparke, Robert Coffin, Sushil Patel and Tanya Lewis.
View institutional ownership trends.
How do I buy shares of Replimune Group?: Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:REPL) was last updated on 12/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial